Today Ionis and Roche have announced more details from the Huntingtin lowering trial. The initial results was released in December […]
New findings indicate that Juvenile Huntington's should be separated into two distinct categories, which in turn may be treated differently. [...]
From 13thto 16thof September, to important meetings took place in Vienna: the EHA Business Meeting and the EHDN Plenary Meeting. [...]
18th of August the cycling race Géants Des Ardennes took place in Liège, Belgium. With the help of team leader Jeroen de [...]
Are you between 18 to 35, living in Europe and affected by a neurological disorder? Then you can participate in […]
The European Medicines Agency has acknowledged the huntingtin lowering drug, RG6042 (previously known as IONIS-HTTRx), as a possible therapy that […]
A newly published survey conducted by EFNA, shows that young Europeans with neurological conditions lives with a fear of isolation […]
HDYO is looking to hold a review meeting on the future direction of the Young Adult Working Group of EHDN […]
Read about the Registery journey from the very beginning to the more recent successor study Enroll-HD. Cristina Ferreira gives you […]
Wave is currently testing a new treatment known as ‘Precision medicine’. The drug only targets the disease-causing protein and leaves [...]
Roche Pharmaceuticals is currently working on their Huntingtin Lowering drug, RG6042 (formerly known as IONIS-HTTRx). In the letter Patient Partnership […]
Funding Partner
Follow us